Kyverna Therapeutics Files Amendment to S-1 Registration Statement

TL;DR

<b>Kyverna Therapeutics, Inc. has filed an S-1/A amendment, signaling progress towards a public offering.</b>

AI Summary

Kyverna Therapeutics, Inc. (KYTX) filed a Amended IPO Registration (S-1/A) with the SEC on February 6, 2024. Kyverna Therapeutics, Inc. filed an amendment (S-1/A) to its registration statement on February 6, 2024. The company is incorporated in Delaware and its principal executive offices are located in Emeryville, CA. The filing is related to the Securities Act of 1933, with SEC file number 333-276523. Kyverna Therapeutics operates in the Biological Products sector (SIC code 2836). The filing indicates the company is a non-accelerated filer, smaller reporting company, and emerging growth company.

Why It Matters

For investors and stakeholders tracking Kyverna Therapeutics, Inc., this filing contains several important signals. This S-1/A filing is a necessary step for Kyverna Therapeutics to proceed with its initial public offering (IPO), allowing it to raise capital for its operations and development. The classification as a non-accelerated filer, smaller reporting company, and emerging growth company provides insights into the company's size and regulatory compliance path.

Risk Assessment

Risk Level: low — Kyverna Therapeutics, Inc. shows low risk based on this filing. The risk is low as this is a routine amendment to a registration statement, not indicating immediate financial distress or significant operational changes.

Analyst Insight

Monitor future filings for updates on the IPO timeline, pricing, and the company's financial performance.

Key Numbers

• 0001994702 — Central Index Key (Kyverna Therapeutics, Inc.)
• 2836 — Standard Industrial Classification (Biological Products (No Diagnostic Substances))
• 831365441 — IRS Number (Kyverna Therapeutics, Inc.)
• 333-276523 — SEC File Number (Registration Statement)
• 5106268331 — Business Phone (Kyverna Therapeutics, Inc.)

Key Players & Entities

• Kyverna Therapeutics, Inc. (company) — Registrant name
• 2024-02-06 (date) — Filing date
• S-1/A (filing_type) — Form type
• 333-276523 (filing_number) — SEC file number
• Delaware (jurisdiction) — State of incorporation
• Emeryville, CA (location) — Principal executive offices
• Peter Maag, Ph.D. (person) — Chief Executive Officer
• 2836 (industry_code) — Standard Industrial Classification

Forward-Looking Statements

• Kyverna Therapeutics will complete its IPO within the next 3-6 months. (Kyverna Therapeutics, Inc.) — medium confidence, target: 2024-08-06

FAQ

Industry Context

Kyverna Therapeutics operates in the biotechnology sector, specifically focusing on biological products.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for detailed amendments and disclosures.
2. Track subsequent SEC filings for updates on the IPO status and prospectus.
3. Analyze the company's business strategy and financial projections once available in the prospectus.

Key Dates

• 2024-02-06: Filing of S-1/A Amendment — Indicates progress in the registration process for a public offering.

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previous filing, indicating updates or corrections to the initial registration statement.

Key Financial Figures

• $20.00 — ffering price per share will be between $20.00 and $21.00. We have applied to list our
• $21.00 — ce per share will be between $20.00 and $21.00. We have applied to list our common sto
• $80 billion — une disease therapies were greater than $80 billion globally in 2021. Despite the availabil
• $170 million — inception, we have raised approximately $170 million in equity capital from investors that h
• $5 billion — ts emergence as a public company with a $5 billion market value in 2022. Dominic Borie,

Filing Documents

• d530411ds1a.htm (S-1/A) — 2552KB
• d530411dex51.htm (EX-5.1) — 7KB
• d530411dex104.htm (EX-10.4) — 29KB
• d530411dex231.htm (EX-23.1) — 2KB
• d530411dexfilingfees.htm (EX-FILING FEES) — 20KB
• g530411g0130102706785.jpg (GRAPHIC) — 2KB
• g530411g0130102706930.jpg (GRAPHIC) — 3KB
• g530411g0130102707044.jpg (GRAPHIC) — 4KB
• g530411g01a26.jpg (GRAPHIC) — 54KB
• g530411g01k22.jpg (GRAPHIC) — 95KB
• g530411g11a01.jpg (GRAPHIC) — 144KB
• g530411g11a02.jpg (GRAPHIC) — 212KB
• g530411g11g01.jpg (GRAPHIC) — 45KB
• g530411g11g02.jpg (GRAPHIC) — 49KB
• g530411g11k99.jpg (GRAPHIC) — 72KB
• g530411g12b01.jpg (GRAPHIC) — 47KB
• g530411g14a01.jpg (GRAPHIC) — 151KB
• g530411g14b02.jpg (GRAPHIC) — 62KB
• g530411g16m69.jpg (GRAPHIC) — 86KB
• g530411g19a10.jpg (GRAPHIC) — 91KB
• g530411g19a20.jpg (GRAPHIC) — 67KB
• g530411g23b23.jpg (GRAPHIC) — 679KB
• g530411g24a95.jpg (GRAPHIC) — 93KB
• g530411g33e74.jpg (GRAPHIC) — 110KB
• g530411g35a25.jpg (GRAPHIC) — 19KB
• g530411g49a38.jpg (GRAPHIC) — 133KB
• g530411g66p38.jpg (GRAPHIC) — 123KB
• g530411g70a70.jpg (GRAPHIC) — 147KB
• g530411g80p01.jpg (GRAPHIC) — 83KB
• g530411g99y21.jpg (GRAPHIC) — 160KB
• 0001193125-24-024683.txt (&nbsp;) — 6330KB

Risk Factors

Risk Factors 16 Special Note Regarding Forward-Looking Statements 86 Market, Industry and Other Data 88

Use of Proceeds

Use of Proceeds 89 Dividend Policy 91 Capitalization 92

Managements Discussion and Analysis of Financial Condition and Results

Managements Discussion and Analysis of Financial Condition and Results of Operations 98

Business

Business 119 Management 171

Executive Compensation

Executive Compensation 184 Certain Relationships and Related Person Transactions 203 Principal Stockholders 207

Description of Capital Stock

Description of Capital Stock 210 Shares Eligible for Future Sale 217 Material U.S. Federal Income Tax Consequences to Non-U.S. Holders 220

Underwriting

Underwriting 225 Legal Matters 236 Experts 236 Where You Can Find Additional Information 236 Index to Financial Statements F-1 You should rely only on the information contained in this prospectus and any free writing prospectus that we may provide to you in connection with this offering. We have not, and the underwriters have not, authorized anyone to provide you with different information or to make any other representations, and we and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information others may give you. We are offering to sell, and seeking offers to buy, shares of our common stock only under circumstances and in jurisdictions where it is lawful to do so. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than its date. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: Neither we nor the underwriters have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for those purposes is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. Numerical figures included in this prospectus have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. i Table of Contents PROSPECTUS SUMMARY This summary highlights selected information that is

View Full Filing

View this S-1/A filing on SEC EDGAR